Free Trial

Kymera Therapeutics (KYMR) SEC Filings & 10K Form

Kymera Therapeutics logo
$23.95 +2.90 (+13.78%)
Closing price 04:00 PM Eastern
Extended Trading
$23.96 +0.00 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Kymera Therapeutics SEC Filings

DateFilerForm TypeView
04/01/2025
7:00 AM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:30 PM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:30 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:30 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:30 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:30 PM
Chiniara Ellen (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
5:00 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
5:00 PM
Chiniara Ellen (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
5:00 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
5:00 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:30 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2025
6:33 AM
Kymera Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/27/2025
6:13 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2025
6:15 AM
Kymera Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/10/2025
9:25 AM
Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SCHEDULE 13G/A
01/14/2025
3:02 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
6:00 AM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2025
6:00 AM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
6:50 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
3:41 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
8:30 AM
Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
11/08/2024
9:52 AM
Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
10/31/2024
7:13 AM
Kymera Therapeutics (Filer)
Form S-3ASR
10/31/2024
6:40 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2024
6:45 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/17/2024
5:20 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2024
3:40 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
5:31 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2024
3:32 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
3:25 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/22/2024
4:06 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
3:15 PM
BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
Form SC 13D/A
08/22/2024
3:03 PM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
4:24 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2024
3:31 PM
Kymera Therapeutics (Filer)
Form 424B5
08/07/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2024
6:15 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/25/2024
5:12 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/23/2024
4:17 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/16/2024
5:00 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2024
3:28 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Warning: “DOGE Collapse” imminent (Ad)

Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.

Click here to see what they’re predicting now.
07/15/2024
3:31 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/09/2024
4:15 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2024
3:16 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/09/2024
3:18 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/28/2024
4:05 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2024
7:30 AM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
Morgan Leigh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
MARAGANORE JOHN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Hrustanovic Gorjan (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
Ridloff Elena (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:01 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2024
7:30 AM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
5:01 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:14 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/13/2024
4:15 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2024
4:23 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2024
4:24 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/07/2024
5:36 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:27 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/23/2024
4:22 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/02/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:15 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/24/2024
3:15 PM
Kymera Therapeutics (Filer)
Form ARS
04/24/2024
3:06 PM
Kymera Therapeutics (Filer)
Form DEF 14A
04/24/2024
3:10 PM
Kymera Therapeutics (Filer)
Form DEFA14A
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:KYMR) was last updated on 4/9/2025 by MarketBeat.com Staff
From Our Partners